Introduction: Comparison of the Bioequivalence of Generic Versus Branded Clozapine
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Clozapine, the first atypical antipsychotic, has been marketed as Clozaril for patients with treatment-refractory schizophrenia since 1989. The patent for Clozaril expired in 1998, and 3 generic formulations of clozapine have received U.S. Food and Drug Administration (FDA) approval. The FDA considers Clozaril (Novartis Pharmaceuticals Corporation) and the 3 generic forms of clozapine manufactured by Zenith Goldline Pharmaceuticals, Mylan Pharmaceutical, and Geneva Pharmaceuticals, which is a subsidiary of Novartis, to be therapeutically equivalent.
J Clin Psychiatry 2001;62(suppl 5):3-3Related Articles